Today the overall results of a Swedish comparative registry study that evaluated the risk of developing prostate cancer after treatment with the two most established methods of treatment of benign prostatic hyperplasia (BPH), which are thermotherapy (TUMT) or surgery (TURP).

The study concludes that patients treated with ProstaLund's method, CoreTherm®, have more than a halved risk of getting a prostate cancer diagnosis, than patients who have had surgery with TURP. The follow-up period was between 1995 and 2019 and the result is statistically significant. Similarly, the risk of prostate cancer-specific mortality is significantly lower for CoreTherm®-treated patients.

"The result may be a "game changer" for the treatment of benign prostatic hyperplasia (BPH). If this information comes to the attention of patients, I think everyone will choose our method," comments Acting CEO Johan Wennerholm.

ProstaLund's hypothesis is that patients treated with CoreTherm® for their prostate enlargement, reduce the risk of developing prostate cancer. For this reason, ProstaLund has initiated a study conducted by the Finnish company Success Clinic Oy. The Swedish Patient Registry and the Cancer Registry have been used as sources. The register study has included all Swedish patients who during the years 1995-2015 had either surgery (TURP, 101,636 men) or thermotherapy (TUMT, CoreTherm® 5,391 men). Patients have been followed until 12/31/2019. The risk that a TURP patient was diagnosed with prostate cancer during the follow-up was 11.7%, compared with 4.7% for the patient who had TUMT. The risk of prostate cancer-specific mortality was greater for TURP patient compared to TUMT patient.

Although the results at first glance give a clear picture and there is a statistical significance between the groups, we will further analyze data from this registry study and look forward to being able to share the findings with the urological profession, both in Sweden and internationally.

For further information, please contact:

Johan Wennerholm, Acting CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-01-11 13:22 CET.

Attachments

ProstaLund's method reduces the risk of developing prostate cancer

© Modular Finance, source Nordic Press Releases